medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 3

<< Back Next >>

Ann Hepatol 2016; 15 (3)

Utility and limitations of APRI and FIB4 to predict staging in a cohort of nonselected outpatients with hepatitis C

de Oliveira AC, El-Bacha I, Vianna MV, Parise ER

Language: English
References: 26
Page: 326-332
PDF size: 154.98 Kb.


ABSTRACT

Background. Chronic hepatitis C(CHC) staging is important for therapeutic decision-making. Identification of noninvasive markers can provide alternatives to liver biopsy. Aim. To assess the value of APRI and FIB4 for CHC fibrosis staging in a cohort of nonselected outpatients from a referral center in Sao Paulo, Brazil. Material and methods. Medical records of 798 adult outpatients were analyzed retrospectively. For calculations of APRI and FIB4, the original descriptions were considered, and markers were compared with degree of liver injury. Results. Overall, 49.3% of participants were female, and mean age was 56.9 ± 12.5 years. Genotype 1 was predominant (71.7 vs. 23.7% genotype 3); 64% had significant fibrosis, 44% had advanced fibrosis, and 28% had cirrhosis. The areas under the receiver operating curve for significant fibrosis, advanced fibrosis, and cirrhosis, respectively, were 0.809, 0.819, and 0.815 for the APRI marker and 0.803, 0.836 and 0.852 for FIB4. Using the recommended cut off values, approximately 30-40% of the patients could not be classified. In the remainder, either APRI or FIB4 alone correctly diagnosed 80-85% of cases. Concomitant or consecutive use of both APRI and FIB4 increased the number of the cases correctly diagnosed only slightly, but also increased the number of patients not classified within the cutoff values. Conclusions. In conclusion, use of the APRI or FIB4 markers for detection of hepatic fibrosis may be a viable alternative at referral centers for treatment of CHC in low- and middleincome countries. Despite relatively good accuracy, a significant number of patients could not be assessed by these methods.


REFERENCES

  1. Mohd Hanafrah K, Groeger J, Flaxman AD, Weirsma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.

  2. Luer GM, Walker BD. Hepatitis C virus infection. N Eng J Med 2001; 345: 41-52.

  3. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of workshop. Hepatology 2002; 36: 227-42.

  4. Serfaty L, Aumaitre H, Chazouileires O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-40.

  5. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 5(Suppl. 1): S152-S160.

  6. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: how safe is it? Ann Int Med 1993; 118: 150-3.

  7. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, et al. Sampling error and intraobserver variations in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.

  8. Colloredo G, Guido M. Sonzoqni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller, the milder the disease. J Hepatology 2003; 39: 239-44.

  9. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.

  10. Guideline for the screening, care and treatment of persons with hepatitis C infection. World Health Organization, April 2014.http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/.

  11. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaran HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.

  12. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, et al. FIB4: an inexpensive and accurate marker of fibrosis in HCV infection: Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.

  13. Sterling RK, Lissen E, Clumick N, Sola R, Correa MC. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.

  14. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatites C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.

  15. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-7.

  16. Sebastiani G, Halfon P, Castera L, Mangias A, Di Marco V, Pirisi M, Voiculescu M, et al. Comparison of three algorithms of noninvasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther 2012; 35: 92-104.

  17. Parise ER, Oliveira AC, Figueredo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Inter 2006; 26: 1095-9.

  18. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y,et al. Performance of aspartate aminotransferase-toplatelet ratio index for staging of hepatitis C related-fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-36.

  19. Shaheen AA, Myer RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systemic review. Hepatology 2007; 46: 912-21.

  20. Holberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, Boscarino JA, et al. Noninvasive serum fibrosis marker for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infection Dis 2013; 57: 240-6.

  21. Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MC, Grigorescu Mircea. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessment in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon 2012; 12: 177-84.

  22. Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009; 16: 300-14.

  23. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.

  24. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74.

  25. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, Bertet J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-08.

  26. Castera L, Sebastiani G, Le Bail B, Ledinghen V, Couzigou P, Albert A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-8.




2020     |     www.medigraphic.com